Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 2/20 | 0.30 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15837092 | 0.79 | CYP1A2 (0.42) | PDK2GABRA1GABRB2KDM1ATDP2 | |
| SCHEMBL3286776 | 0.76 | PDK2 (0.41) | PDK2KCNK2KDM1ATDP2APP | |
| SCHEMBL14580696 | 0.76 | PDK2 (0.41) | PDK2KCNK2KDM1ATDP2APP | |
| SCHEMBL204595 | 0.76 | PDK2 (0.43) | PDK2KCNK2KDM1ATDP2APP | |
| SCHEMBL15836738 | 0.76 | BACE1 (0.47) | PDK2BACE1 | |
| SCHEMBL20221038 | 0.75 | KDM1A (0.34) | PDK2KCNK2GABRA1GABRB2KDM1A | |
| SCHEMBL14580695 | 0.75 | CA1 (0.42) | PDK2KCNK2KDM1ATDP2CA1 | |
| SCHEMBL13337301 | 0.75 | KCNK2 (0.42) | PDK2KCNK2KDM1ATDP2APP | |
| SCHEMBL12306672 | 0.75 | KCNK2 (0.42) | PDK2KCNK2KDM1ATDP2APP | |
| SCHEMBL15969314 | 0.74 | SMN1; SMN2 (0.40) | PDK2KCNK2LMNAPKMBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963478-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-08 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | PDK2 1352/4885KCNK2 3399/4885GABRA1 4319/4885 |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | PDK2 1352/4885KCNK2 3399/4885GABRA1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.